U.S. markets close in 4 hours 12 minutes
  • S&P 500

    3,889.91
    +44.83 (+1.17%)
     
  • Dow 30

    31,296.24
    +258.56 (+0.83%)
     
  • Nasdaq

    11,561.95
    +200.09 (+1.76%)
     
  • Russell 2000

    1,765.92
    +38.37 (+2.22%)
     
  • Crude Oil

    104.04
    +5.51 (+5.59%)
     
  • Gold

    1,740.90
    +4.40 (+0.25%)
     
  • Silver

    19.23
    +0.07 (+0.37%)
     
  • EUR/USD

    1.0164
    -0.0021 (-0.20%)
     
  • 10-Yr Bond

    2.9910
    +0.0780 (+2.68%)
     
  • GBP/USD

    1.1999
    +0.0077 (+0.65%)
     
  • USD/JPY

    135.9460
    +0.0310 (+0.02%)
     
  • BTC-USD

    20,859.23
    +769.92 (+3.83%)
     
  • CMC Crypto 200

    455.05
    +10.74 (+2.42%)
     
  • FTSE 100

    7,200.44
    +92.67 (+1.30%)
     
  • Nikkei 225

    26,490.53
    +382.88 (+1.47%)
     

Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Immunovant
Immunovant

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it will report its fourth quarter and full-year 2022 financial results before the open of the U.S. financial markets on Wednesday, June 8, 2022. The company also plans to host a webcast and conference call on Wednesday, June 8, 2022 at 8:00 AM ET.

Following prepared remarks, the call will include a live question-and-answer session for the investment community. To access the webcast and the presentation being shared on the call, please visit Immunovant’s website at https://www.immunovant.com/investors/news-events.

Participants may also dial in using the numbers provided below:
Toll Free: 1-877-407-9039
Toll/International: 1-201-689-8470

An archived recording of the webcast will be available on Immunovant’s website for a limited time following its conclusion.

About Immunovant, Inc. 

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. Our investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com.

Contact:
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com